Blackstone Entrepreneurs Network Selects Symberix
Symberix joins the Blackstone Entrepreneurs Network portfolio — gaining mentorship and strategic support for microbiome drug development.
Read more →Awards, publications, and milestones from Symberix.
Symberix joins the Blackstone Entrepreneurs Network portfolio — gaining mentorship and strategic support for microbiome drug development.
Read more →Symberix selected as a featured showcase presenter at the CED Life Science Conference, highlighting our first-in-class microbiome inhibitor pipeline.
Read more →Genetic Engineering News highlights Symberix in a feature article on microbiome-targeted therapeutics and bacterial enzyme inhibitors.
Read more →The human microbiome encodes 100x more genes than our genome, creating thousands of bacterial enzymes ideal for novel drug discovery.
Read more →New manuscript on the human gusome — the gut-microbiome metagenome — published by Symberix co-founder Dr. Matt Redinbo and collaborators.
Read more →Symberix awarded multiple NIH and foundation grants supporting microbiome-targeted therapeutic research and preclinical candidate development.
Read more →National Cancer Institute (NCI) awards Symberix a Phase 1 SBIR contract to develop microbiome-targeted inhibitors reducing chemotherapy toxicity.
Read more →October 2018 update from Symberix: pipeline milestones, funding, publications and conference presentations in microbiome drug discovery.
Read more →Scientific American highlights Symberix research on gut bacterial enzymes driving chemotherapy side effects and microbiome-targeted inhibitors.
Read more →Symberix chosen to present at CED Startup Stadium — pitching microbiome-targeted cancer therapeutics to investors and industry leaders.
Read more →Symberix secures Phase II SBIR funding to advance first-in-class microbiome inhibitor candidates through preclinical development milestones.
Read more →Symberix CEO delivers keynote at Translational Microbiome Conference on microbiome-targeted therapeutics and drug toxicity reduction.
Read more →Nature features Symberix microbiome research: targeting gut bacterial enzymes to improve chemotherapy tolerability and patient outcomes.
Read more →Nature Reviews article cites Symberix microbiome-targeted therapeutics approach for reducing drug toxicity and improving treatment outcomes.
Read more →PNAS publishes Symberix collaborative research on gut bacterial beta-glucuronidase inhibitors reducing irinotecan-induced toxicity.
Read more →Symberix CEO delivers keynote at American Association for Cancer Research (AACR) on microbiome-targeted therapeutics in oncology.
Read more →Symberix awarded additional funding from Carolina KickStart to accelerate microbiome-targeted therapeutic development at UNC Chapel Hill.
Read more →Symbiotic drug design at Symberix: selectively inhibit gut bacterial enzymes causing drug toxicity without disrupting the human microbiome.
Read more →US Patent and Trademark Office issues notice of allowance for a microbiome inhibitor patent licensed exclusively to Symberix Inc.
Read more →